A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Cannot have received: HER3-targeted therapy

With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs

Cannot have received: CAR-T cell therapy

With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs

Cannot have received: topoisomerase I inhibitor

Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors

Cannot have received: antibody-drug conjugate

Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors

Cannot have received: allogeneic bone marrow transplantation

Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation

Cannot have received: solid organ transplantation

Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation